AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors

Company Performance - AngioDynamics' stock closed at $5.37, reflecting a decrease of -0.74% from the previous trading day, which is less than the S&P 500's daily loss of 0.65% [1] - The stock has declined by 12.32% over the past month, underperforming the Medical sector's gain of 1.98% and the S&P 500's gain of 3.27% [1] - The upcoming earnings report is expected to show an EPS of -$0.14, a significant drop of 366.67% from the same quarter last year, with projected quarterly revenue of $76.71 million, down 4.96% year-over-year [1] Annual Projections - For the full year, earnings are projected at -$0.43 per share and revenue at $316.15 million, indicating changes of -616.67% and -6.67% respectively from the prior year [2] - Recent analyst estimate revisions are crucial as they reflect near-term business trends, with positive revisions indicating confidence in the company's performance [2] Zacks Rank and Industry Performance - AngioDynamics currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 10.9% in the past month [3] - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 56, placing it in the top 23% of over 250 industries [3] - The Zacks Industry Rank evaluates the strength of industry groups, showing that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [3]